Login to Your Account



Sinovac Q1 results boosted by strong vaccine sales growth

By Cornelia Zou
Staff Writer

Wednesday, May 28, 2014

HONG KONG – Growing domestic and international sales of vaccines buoyed strong growth for one of China's top biotechs, as reflected in its first quarter results for 2014. Beijing-based Sinovac Biotech Ltd. (NASDAQ:SVA) reported $13.5 million in sales, a jump of 34.8 percent from $10.1 million during the same period in 2013. Sinovac's shares lost 21 cents Thursday, to close at $6.06.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription